{"id":"NCT01251276","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Hepatitis B Challenge Dose in Adults (V232-059-10)","officialTitle":"A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥50 Years Old) Vaccinated With a Primary Series of an Hepatitis B Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11-30","primaryCompletion":"2011-04-12","completion":"2011-04-12","firstPosted":"2010-12-01","resultsPosted":"2017-08-28","lastUpdate":"2022-09-13"},"enrollment":204,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"Modified Process Hepatitis B Vaccine","otherNames":["HBVaxPro"]}],"arms":[{"label":"Modified Process Hepatitis B Vaccine in Base Study","type":"EXPERIMENTAL"},{"label":"ENGERIX-B™ Vaccine in Base Study","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to describe the Seroprotection Rate (SPR) at least 2 years following completion of a primary series with a hepatitis B vaccine (Base Study V232-059, NCT00440531) and 1 month following a challenge dose with a Modified Process Hepatitis B vaccine.","primaryOutcome":{"measure":"Percentage of Seroresponders Before and After the Challenge Vaccination","timeFrame":"Predose (Day 1) and 1 month after challenge dose (Month 1)","effectByArm":[{"arm":"Modified Process Hepatitis B Vaccine in Base Study","deltaMin":45.5,"sd":null},{"arm":"ENGERIX-B™ Vaccine in Base Study","deltaMin":58.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25996838"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":96},"commonTop":["Injection-site pain","Injection-site erythema","Injection-site swelling"]}}